FDA approves neoadjuvant/adjuvant duravlumab for resectable non–small cell lung cancer. FDA. August 15, 2024. Accessed March 3, 2025. A study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable non–small cell lung cancer (AEGEAN). ClinicalTrials.gov. Updated January...
研究结果表明,虽然PD-L1高表达患者的ORR更高,但取得疗效的患者中,无论其PD-L1表达水平,疗效均较持久。抗PD-L1单抗durvalumab用于既往经过多线治疗后的晚期NSCLC患者,有较好的临床疗效,且耐受性好。 参考文献:《Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): ...
约1/3的非小细胞肺癌 (non-small cell lung cancer ,NSCLC) 患者在诊断时患有 III 期局部晚期疾病。铂类放化疗是不可切除的 III 期NSCLC的标准治疗方法。接受放化疗的患者的中位无进展生存期很差。作为不能手术的 III 期NSCLC同步放化疗(concurrent chemoradiotherapy,cCRT)后的免疫加强巩固治疗,durvalumab 可以增...
参考来源: 1. Antonia, S.J., et al., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med, 2017. 377(20): p. 1919-1929. 2. Antonia, S.J., et al., Overall Survival with Durvalumab...
Introduction: In non-small cell lung cancer (NSCLC), immunotherapy is one of today's most important and ground-breaking systemic treatments, mainly represented by antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death protein 1 or ligand 1 (PD-1/PD-L1). ...
前沿信息、药物最新临床、群聊经典案例、专家大咖点评面面俱到！我们每天100%的认真和努力，为您的抗癌之路保驾护航！欢迎点击订阅。”参考文献 1．FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing 2. http://www.nejm.org/doi/full/10.1056/NEJM oa1709937 ...
7. Paz-Ares L, Spira A, Raben D, et al: Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol 31:798-806, 2020 声明:本资料中...
参考来源:1. Antonia, S.J., et al., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med, 2017. 377(20): p. 1919-1929. 2. Antonia, S.J., et al., Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of...
7. Paz-Ares L, Spira A, Raben D, et al: Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol 31:798-806, 2020 声明:本资料中涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见或指导。
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study (J Clin Oncol ;IF:50.717) CORRESPONDENCE TO: Melissa L. Johnson, MD, Sarah Cannon Research Institute—Tennessee Oncology, 250 25th...